Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC
Status:
Unknown status
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
To determine whether in docetaxel pretreated advanced NSCLC patients with favorable clinical
parameter(s) gefitinib can produce different outcomes from patients without favorable
clinical parameter treated with irinotecan.